Atorvastatin promotes the healing of alveolar bone defect in rats and its effect on Wnt/β-catenin signaling pathway

doi:10.19439/j.sjos.2024.02.004

Abstract

Abstract: PURPOSE: To investigate the therapeutic effect of atorvastatin on alveolar bone defect model in rats, and to observe the effect of atorvastatin on Wnt/β-catenin. METHODS: Thirty rats were randomly divided into normal group (group N), model group (group M) and atorvastatin administration group (group ATV). Except group N, bone defects were made in other rats' alveolar bone to construct alveolar bone defect model. After successful modeling, 20 mg/kg atorvastatin suspension was administered by gavage in group ATV, and the same amount of sodium carboxymethyl cellulose solution was administered by gavage in group N and group M for twenty-one days. After the last administration, tail vein blood was collected to detect the concentrations of serum osteoprotegerin (OPG), alkaline phosphatase (ALP) and osteocalcin (BPG). H-E staining was used to observe the pathological changes of maxillary defect area, and lane Sandhu score was performed. Tartrate resistant acid phosphatase(TRAP) staining was used to detect the number of osteoclasts in the defect area. Real time fluorescence quantitative PCR(RT-qPCR) and Western blot(WB) were used to detect Wnt, β-catenin and Runx2 mRNA protein expression. Statistical analysis was performed with SPSS 23.0 software package. RESULTS: Compared with group N, the concentrations of OPG, ALP, BGP and Lane Sandhu score in group M decreased, and the number of osteoclasts increased. Compared with group M, the concentrations of OPG, ALP and BGP and lane Sandhu score in group ATV increased, and the number of osteoclasts decreased. After H-E staining, the amount of bone formation in maxillary defect area in group N was more,there was fewer bone tissues in the defect area in group M, the amount of bone tissues in the defect area increased in group ATV. Compared with group N, Wnt, β-catenin and Runx2 mRNA protein decreased. Compared with group M, Wnt, β-catenin and Runx2 mRNA protein expression increased. CONCLUSIONS: Atorvastatin can promote the healing of alveolar bone defect and accelerate bone reconstruction in rat models. This effect may be related to the activation of Wnt/β-catenin signaling pathway.

Key words: Atorvastatin, Alveolar bone defect, Osteoclasts, β-catenin, Runx2

CLC Number:

R782.1

CHEN Hong-li, YIN Gang, ZHANG Hai-juan. Atorvastatin promotes the healing of alveolar bone defect in rats and its effect on Wnt/β-catenin signaling pathway[J]. Shanghai Journal of Stomatology, 2024, 33(2): 130-134.

References

[1] Monje A, Pons R, Insua A, et al.Morphology and severity of peri-implantitis bone defects[J]. Clin Implant Dent Relat Res, 2019, 21(4): 635-643.
[2] Chiapasco M, Casentini P.Horizontal bone-augmentation procedures in implant dentistry: prosthetically guided regeneration[J]. Periodontol 2000, 2018, 77(1): 213-240.
[3] Frizzera F, Oliveira GJPL, Shibli JA, et al.Treatment of peri-implant soft tissue defects: a narrative review[J]. Braz Oral Res, 2019, 33(Suppl 1): e073.
[4] Nibali L, Sultan D, Arena C,et al.Periodontal infrabony defects: systematic review of healing by defect morphology following regenerative surgery[J]. J Clin Periodontol, 2021, 48(1): 100-113.
[5] 栗亮, 韩新, 李虎, 等. 阿仑膦酸钠联合阿托伐他汀治疗糖尿病合并骨质疏松的临床疗效及安全性meta分析[J]. 中国骨质疏松杂志, 2020, 26(12): 7-12.
[6] 龚海虹, 林志航, 林志强. 三种不同他汀类药物对去卵巢诱导骨质疏松大鼠骨密度的影响[J]. 中国骨质疏松杂志, 2019, 25(4): 518-522.
[7] 易子欣, 易婷, 姚心雨, 等. Micro-CT检测STZ诱导的糖尿病大鼠牙槽骨微结构改变[J]. 西南医科大学学报, 2021, 44(2): 110-113.
[8] 王琮仁, 孔长庚, 郭祥, 等. 阿托伐他汀通过NFATc1信号通路促进大鼠骨质疏松性骨折愈合[J]. 临床外科杂志, 2022, 30(6): 583-585.
[9] Yuan Y, Zhang H, Huang H. microRNAs in inflammatory alveolar bone defect: a review[J]. J Periodontal Res, 2021, 56(2): 219-225.
[10] Lu J, Wang Z, Zhang H, et al.Bone graft materials for alveolar bone defects in orthodontic tooth movement[J]. Tissue Eng Part B Rev, 2022, 28(1):35-51.
[11] 苏晓. 阿仑膦酸钠联合阿托伐他汀对糖尿病合并骨质疏松患者骨密度及骨代谢水平的影响[J]. 山西医药杂志, 2019, 48(22): 2769-2771.
[12] 王青, 罗欢, 徐丽丽, 等. 阿托伐他汀钙对成骨前体细胞(3T3-E1)增殖与分化的影响及其与内质网应激的联系[J]. 中国骨质疏松杂志, 2018, 24(7): 910-913.
[13] 汪瑜, 熊德建, 罗梅懿, 等. 葛根素联合阿托伐他汀用药对激素性股骨头缺血性坏死Hedgehog信号通路的影响[J]. 四川医学, 2019, 40(6): 552-557.
[14] Dolci GS, Ballarini A, Gameiro GH, et al.Atorvastatin inhibits osteoclastogenesis and arrests tooth movement[J]. Am J Orthod Dentofacial Orthop, 2018, 153(6): 872-882.
[15] Zhang F, Attarilar S, Xie K, et al.Carfilzomib alleviated osteoporosis by targeting PSME1/2 to activate Wnt/β-catenin signaling[J]. Mol Cell Endocrinol, 2021, 540(15): 111520.
[16] Suo J, Feng X, Li J, et al. VGLL4 promotes osteoblast differentiation by antagonizing TEADs-inhibited Runx2 transcription[J]. Sci Adv, 2020, 6(43): eaba4147.
[17] Hong W, Wei Z, Qiu Z, et al.Atorvastatin promotes bone formation in aged apoE-/- mice through the Sirt1-Runx2 axis[J]. J Orthop Surg Res, 2020, 15(1): 303-310.
[18] Gao X, Zhang L, Gu G, et al.The effect of oxLDL on aortic valve calcification via the Wnt/β-catenin signaling pathway: an important molecular mechanism[J]. J Heart Valve Dis, 2015, 24(2):190-196.